Salim Syed’s rating is based on a combination of encouraging developments surrounding Crispr Therapeutics AG. Firstly, the pricing of Casgevy in Saudi Arabia appears to be around $2 million per ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been given an average recommendation of “Hold” by the nineteen brokerages that are covering the company, Marketbeat Ratings reports. Two ...

Leerink Partners analyst Mani Foroohar maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) on November 5 and set a ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other promising ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Crispr Therapeutics AG (NASDAQ:CRSP) on Thursday, setting a price target of $166, which is ...

PFG Investments LLC lessened its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 7.3% during the third quarter, according to its most recent disclosure with the ...

ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...